Macquarie University

Dr Seong Beom (Charlie) Ahn

Dr. Ahn is a research fellow at Macquarie University, leading the innovative Cancer Proteomics Research Group. His pioneering research is dedicated to the discovery of protein biosignatures from blood and tissues, aimed at the early detection of colorectal cancer (CRC) and the identification of high-risk tumour recurrence in stage II CRC patients, using advanced proteomics and bioinformatics technologies.

Dr Ahn obtained a PhD (2008) in biological engineering from the University of QLD. He has been a vital force in cancer research since joining the Cancer Proteomics Research Group (previously led by Prof Baker) at Macquarie University in 2012. In 2016, his potential for groundbreaking work was recognised through the highly competitive Cancer Institute NSW Early Career Research (ECR) Fellowship, focusing on "Next Generation Colorectal Cancer Biomarkers and Treatment." This prestigious acknowledgment was followed by the Susan and John Freeman Cancer Research Award from the Cancer Council NSW (CCNSW) in 2019, highlighting the significant research into blood-based early-stage CRC screening.

Continuing to gain recognition for his impactful work, Dr. Ahn received a CCNSW project grant in 2023 for the project "Protein Biosignatures for Predicting Tumour Recurrence of Stage II Colorectal Cancer." This project not only underscores the potential of his research in changing clinical practices but also highlights the ongoing support from leading cancer research organisations.

Throughout his career, Dr. Ahn has assembled a highly skilled multidisciplinary team, including surgeons, pathologists, medical oncologists, biostatisticians, biochemists, and patient advocates. Together, they have developed a comprehensive multi-omics platform integrating proteomics, metabolomics, genomics, meta-transcriptomics, and cell-omics. This platform facilitates not just CRC research but also the analysis of various cancers through diverse biological samples, demonstrating Dr. Ahn's commitment to innovation and collaboration in the fight against cancer.

More  researchers